[1]王小维,张清媛.细胞周期蛋白依赖性激酶4/6抑制剂治疗乳腺癌研究进展[J].新乡医学院学报,2018,35(8):746-750.[doi:10.7683/xxyxyxb.2018.08.025]
 N/A.N/A[J].Journal of Xinxiang Medical University,2018,35(8):746-750.[doi:10.7683/xxyxyxb.2018.08.025]
点击复制

细胞周期蛋白依赖性激酶4/6抑制剂治疗乳腺癌研究进展
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
35
期数:
2018年8
页码:
746-750
栏目:
综述
出版日期:
2018-08-05

文章信息/Info

Title:
N/A
作者:
王小维张清媛
(哈尔滨医科大学附属肿瘤医院肿瘤内三科,黑龙江 哈尔滨 150081)
Author(s):
N/A
N/A
关键词:
乳腺癌细胞周期蛋白依赖性激酶4/6抑制剂视网膜母细胞瘤蛋白安全性
Keywords:
N/A
分类号:
R737.9
DOI:
10.7683/xxyxyxb.2018.08.025
文献标志码:
A
摘要:
生长信号过表达和细胞周期调控点缺失是肿瘤细胞生长的重要特征。在肿瘤治疗方面,通过细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂重建细胞周期调控极具吸引力。目前,已有3种选择性靶向CDK4/6抑制剂被研发。本文总结了CDK4/6抑制剂治疗乳腺癌的研究进展,以期进一步认识和应用CDK4/6抑制剂。
Abstract:
N/A

参考文献/References:

[1] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2] TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[3] 郑莹,吴春晓,张敏璐.乳腺癌在中国的流行状况和疾病特征[J].中国癌症杂志,2013,23(8):561-563.
[4] GONG Y,LIU Y R,JI P,et al.Impact of molecular subtypes on metastatic breast cancer patients:a SEER population-based study[J].Sci Rep,2017,7:45411.
[5] NADJI M,GOMEZ-FERNANDEZ C,GANJEI-AZAR P,et al.Immunohistochemistry of estrogen and progesterone receptors reconsidered:experience with 5993 breast cancers[J].Am J Clin Path,2005,123(1):21-27.
[6] MANNING G,WHYTE D B,MARTINEZ R,et al.The protein kinase complement of the human genome[J].Science,2002,298(5600):1912-1934.
[7] ROSKOSKI R J R.Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs[J].Pharmacol Res,2016,107:249-275.
[8] 崔艳丽,金玉洁,田苗.周期蛋白依赖性激酶4/6抑制剂palbociclib[J].现代药物与临床,2014,29(10):1178-1182.
[9] FINN R S,ALESHIN A,SLAMON D J.Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers[J].Breast Cancer Res,2016,18(1):17.
[10] LANGE C A,YEE D.Killing the second messenger:targeting loss of cell cycle control in endocrine-resistant breast cancer[J].Endocr Relat Cancer,2011,18(4):C19-C24.
[11] DICKSON M A.Molecular pathways:CDK4 inhibitors for cancer therapy[J].Clin Cancer Res,2014,20(13):3379-3383.
[12] MATSUSHIME H,EWEN M E,STROM D K,et al.Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins[J].Cell,1992,71(2):323-334.
[13] MEYERSON M,HARLOW E.Identification of G1 kinase activity for CDK6,a novel cyclin D partner[J].Mol Cell Biol,1994,14(3):2077-2086.
[14] BATES S,BONETTA L,MACALLAN D,et al.CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1[J].Oncogene,1994,9(1):71-79.
[15] SATYANARAYANA A,KALDIS P.Mammalian cell-cycle regulation:several CDKs,numerous cyclins and diverse compensatory mechanisms[J].Oncogene,2009,28(33):2925-2939.
[16] SHERR C J.D-type cyclins[J].Trends Biochem Sci,1995,20(5):187-190.
[17] DICKSON M A,SCHWARTZ G K.Development of cell-cycle inhibitors for cancer therapy[J].Curr Oncol,2009,16(2):36-43.
[18] VANARSDALE T,BOSHOFF C,ARNDT K T,et al.Molecular pathways:targeting the cyclin D-CDK4/6 axis for cancer treatment[J].Clin Cancer Res,2015,21(13):2905-2910.
[19] FINN R S,DENING J,CONKLIN D,et al.PD 0332991,a selective cyclin D kinase 4/6 inhibitor,preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro[J].Breast Cancer Res,2009,11(5):R77.
[20] FINN R S,CROWN J P,LANG I,et al.The cyclin-dependent kinase 4/6inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive,HER2- negative,advanced breast cancer(PALOMA-1/TRIO-18):a randomized phase 2 study[J].Lancet Oncol,2015,16(1):25-35.
[21] FINN R S,MARTIN M,RUGO H S,et al.Palbociclib and letrozole in advanced breast cancer[J].N Engl J Med,2016,375(20):1925-1936.
[22] TURNER N C,RO J,ANDRE F,et al.Palbociclib in hormone-receptor-positive advanced breast cancer[J].N Engl J Med,2015,373(3):209-219.
[23] DE GROOT A F,KJIJPERS C J,KROEP J R.CDK4/6 inhibition in early and metastatic breast cancer:a review[J].Cancer Treat Rev,2017,60:130-138.
[24] HORTOBAGYI G N,STEMMER S M,BURRIS H A,et al.Ribociclib as first-line therapy for HR-positive,advanced breast cancer[J].N Engl J Med,2016,375(18):1738-1748.
[25] PATNAIK A,ROSEN L S,TOLANEY S M,et al.Abstract CT232:Clinical activity of LY2835219,a novel cell cycle inhibitor selective for CDK4 and CDK6,in patients with metastatic breast cancer[J].Cancer Res,2014,74(19 Suppl):CT232-CT232.
[26] DICKLER M N,TOLANEY S,RUGO H S,et al.MONARCH 1,a phase 2 study of abemaciclib,a CDK4 and CDK6 inhibitor,as a single agent,in patients with refractory HR+/HER2-metastatic breast cancer[J].Clin Cancer Res,2017,23(17):5218-5224.
[27] PATNAIK A,ROSEN L S,TOLANEY S M,et al.Efficacy and safety of abemaciclib,an inhibitor of CDK4 and CDK6,for patients with breast cancer,non-small cell lung cancer,and other solid tumors[J].Cancer Discov,2016,6(7):740-753.
[28] GELBERT L M,CAI S,LIN X,et al.Preclinical characterization of the CDK4/6 inhibitor LY2835219:in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine[J].Invest New Drugs,2014,32(5):825-837.
[29] INFANTE J R,CASSIER P A,GERECITANO J F,et al.A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas[J].Clini Cancer Res,2016,22(23):5696-5705.
[30] DEMICHELE A,CLARK A S,TAN K S,et al.CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer:phase Ⅱ activity,safety,and predictive biomarker assessment[J].Clin Cancer Res,2015,21(5):995-1001.
[31] SLEDGE G W J R,TOI M,NEVEN P,et al.MONARCH 2:abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy[J].J Clin Oncol,2017,35(25):2875-2884.
[32] LEO A D,TOI M,CAMPONE M,et al.236O_PRMONARCH 3:abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer[J].Ann Oncol,2017,28(suppl 5):5556-5564.
[33] MA C X,GAO F,LUO J,et al.NeoPalAna:neoadjuvant palbociclib,a cyclin-dependent kinase 4/6 inhibitor,and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer[J].Clini Cancer Res,2017,23(15):4055-4065.
[34] CHOW L W,LAM C K,LOO W T.Abstract P6-11-04:OOTR-N007:a phase Ⅱ neoadjuvant study of letrozole plus palbociclib in postmenopausal patients with ER positive,HER2 negative breast cancer[J].Cancer Research,2015,75(9 Suppl):P6.
[35] KWAPISZ D.Cyclin-dependent kinase 4/6 inhibitors in breast cancer:palbociclib,ribociclib,and abemaciclib[J].Breast Cancer Res Treat,2017,166(1):41-45.
[36] CURIGLIANO G,GOMEZ P P,MERICBERNSTAM F,et al.Ribociclib plus letrozole in early breast cancer:a presurgical,window-of-opportunity study[J].Breast,2016,28:191-198.
[37] HURVITZ S,ABAD M F,ROSTORFER R,et al.Breast cancer,early stage Interim results from neo MONARCH:a neoadjuvant phase Ⅱ study of abemaciclib in postmenopausal women with HR+/HER2-breast cancer (BC)[J].Ann Oncol,2016,27(suppl 6):Vi552-Vi587.

相似文献/References:

[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 . 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]王 乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.
[10]杨绍英,刘朝荣,张志刚,等.乳腺癌新辅助化学治疗前后雌激素受体、乳激素受体、Ki-67抗原和人类表皮生长因子受体-2的表达[J].新乡医学院学报,2017,34(2):125.[doi:10.7683/xxyxyxb.2017.02.012]
 YANG Shao-ying,LIU Chao-rong,ZHANG Zhi-gang,et al.Expressions of estrogen receptor,progestin recetor,Ki-67 antigen,and human epidermal growth factor receptor 2 before and after neoadjuvant chemotherapy in patients with breast cancer[J].Journal of Xinxiang Medical University,2017,34(8):125.[doi:10.7683/xxyxyxb.2017.02.012]

更新日期/Last Update: 2018-08-05